May 15, 2012 –– As EuroPCR 2012 gets underway, Medtronic Inc.announced that the Resolute Integrity Coronary Stent System has received European regulatory approval for several new indications...
May 17, 2012 — Boston Scientific Corp. announces CE mark and European market launch of the Innova Self-Expanding Bare-Metal Stent System, which is designed to treat peripheral vascular...
May 15, 2012 —A simple clinical assessment performed in the doctor’s office can identify patients who are at high risk for stroke and other major complications following a...
May 14, 2012 -- Two types of stent systems are both effective in treating patients who have severe forms of peripheral artery disease (PAD), according to results of the MOBILITY trial...
May 10, 2012 — New research confirms thrombus aspiration (TA) during percutaneous coronary intervention (PCI) in patients with acute ST-segment elevation myocardial infarction (STEMI) provides...
May 4, 2012 - The U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the Medinol Ltd. Presillion plus cobalt chromium (CoCr) coronary...
April 23, 2012 - Abbott and St. Jude Medical announced ChoiceAlliance, a multi-year joint initiative that provides mutual U.S. customers access to a robust portfolio of interventional...
April 12, 2012 – Abbott announced approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the next-generation Xience Prime Everolimus-Eluting Coronary Stent System for the...
April 16, 2012 - 480 Biomedical announced that it has initiated the first human trial of its groundbreaking Stanza self-expanding bioresorbable scaffold for the treatment of peripheral artery...
April 12, 2012 — The Maryland General Assembly set a high bar for the nation and showed its commitment to patients by passing legislation establishing an independent review of the placement of...
April 6, 2012 — Boston Scientific Corp. announced results from a quantitative coronary angiographic (QCA) analysis of the incidence of longitudinal stent deformation in the PERSEUS and PLATINUM...
April 5, 2012 — Arterial Remodeling Technologies (ART) reported yesterday that in vivo data strongly suggest that its next-generation bioresorbable stent promotes positive arterial...
Boston Scientific announced its support of the HORIZONS II AMI clinical trial, which is designed to evaluate the safety and efficacy of the Promus Element Plus everolimus-eluting platinum chromium...
Two-year follow-up data from the pivotal PLATINUM Workhorse trial comparing the safety and effectiveness of the Promus Element and Xience V everolimus-eluting coronary stents demonstrated superior...
March 29, 2012 — In the second year of an ongoing trial, the Resolute zotarolimus-eluting stent (Medtronic) achieved a low rate of stent thrombosis, cardiac death, target vessel heart attack and...
Biodegradable polymer drug-eluting stents (DES) provide better long-term safety and efficacy than durable polymer DES, according to findings from an analysis of three major clinical trials — ISAR-...
March 20, 2012 - MarBlue Medical announced the global product launch of its CE-marked drug-eluting balloon (DEB) Protege as well as its CoCr stent on DEB Pioneer. The full market launch of the new...
March 16, 2012 — The U.S. Food and Drug Administration (FDA) approved the premarket approval (PMA) application for the Covidien EverFlex self-expanding peripheral stent system.
March 16, 2012 - Depression increases the risk of death in patients who have a coronary stent implanted. After seven years of follow up, depressed patients were 1.5 times more likely to have died...
March 9, 2012 — Boston Scientific Corp. announced the launch of the Promus Element everolimus-eluting coronary stent system in Japan. The product was recently approved by the Ministry of Health,...
March 6, 2012 — In a development that brings advanced combination therapy treatment of peripheral artery disease (PAD) to Japanese patients for the first time, Cook Medical has received PMDA...
The U.S. Food and Drug Administration (FDA) granted the first coronary stent indication for use in patients experiencing an acute myocardial infarction (AMI), or heart attack. The Boston...
February 6, 2012 — A medical technology company commercializing the world's first and only self-apposing stent to treat acute myocardial infarction (AMI), announced today that the APPOSITION III...
February 1, 2012 — Boston Scientific announced the first patient use and European market launch of the Promus Element Plus everolimus-eluting coronary stent system. The first patient implant in...
January 23, 2012 – Boston Scientific Corp. said the U.S. District Court for the District of New Jersey has found all the asserted patents for a coronary stent in a lawsuit brought by Johnson...
January 18, 2012 — Boston Scientific reported nine-month clinical endpoint data from its ORION trial, demonstrating positive outcomes for the Epic self-expanding nitinol stent in patients with...
January 9, 2012 – A registry that includes every patient in Sweden having percutaneous coronary intervention (PCI) found use of newer generation drug-eluting stents (DES) is associated with lower...
January 4, 2012 – ECRI, an independent nonprofit that researches the best approaches to improving patient care, listed 10 health technology issues that hospital leaders should have on their watch...
Abbott announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug-eluting bioresorbable vascular scaffold (...
December 20, 2011 – Boston Scientific reported positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the Ion (Taxus...
December 19, 2011 – The Maryland Chapter of the American College of Cardiology (ACC) and the Society for Cardiovascular Angiography and Interventions (SCAI) reiterated their call for the state of...
Boston Scientific recently announced U.S. Food and Drug Administration (FDA) approval for the Promus Element Plus everolimus-eluting platinum chromium coronary stent system, the company's next-...
December 9, 2011 — Abbott announced Thursday the initiation of ABSORB II, the first randomized, controlled, multi-center clinical trial evaluating the safety, efficacy and performance of the...
November 22, 2011 — The thoracic aorta can pose major problems for endovascular repair when there are tortuous segments. Navigating an endograft through difficult territory can prevent its precise...
November 22, 2011 — The question remains whether patency rates for heparin-bonded polytetrafluoroethylene (PTFE) grafts are better than traditional PTFE bypasses; whether these types of grafts...
November 22, 2011 — The controversial subject of “indiscriminate” stenting to treat asymptomatic carotid stenosis (ACS) was addressed at the 38th annual VEITH Symposium.
November 21, 2011 — Micell Technologies Inc. announced the release of preliminary data from the first-in-human clinical study of the MiStent Sirolimus Drug Eluting Coronary Stent System (MiStent...
November 21, 2011 - Frank J. Veith, M.D., founder and chairman of the VEITH symposium, the William J. von Liebig Chair in Vascular Surgery, Cleveland Clinic and New York University Medical Center...
November 15, 2011 – The risk of late stent thrombosis (ST) in the first generation of drug-eluting stents continues for up to seven years after implantation, and certain...
November 15, 2011 – A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to both bare metal stents alone and drug-eluting...
November 15, 2011 – Abbott announced positive long-term data from the two-stage ABSORB trial, which is evaluating the Absorb drug-eluting bioresorbable vascular scaffold (BVS) for the treatment of...
November 15, 2011 – Results from the PROFI study indicate that the use of a proximal balloon occlusion in carotid artery stenting lead to fewer cerebral ischemic lesions...
November 15, 2011 — Researchers have found polymer-free amphilimus-eluting stents in de novo coronary artery lesions showed a significantly lower in-stent late loss at six months compared...
November 15, 2011 — A new clinical trial is testing the efficacy of rotational atherectomy (or rotablation, a process of drilling through plaque deposits) prior to implantation of a drug-eluting...
November 15, 2011 — A clinical trial has shown a drug-eluting stent (DES) with a bioabsorbable polymer has comparable outcomes to a DES with a durable polymer. Results of the EVOLVE clinical trial...
November 14, 2011 – OrbusNeich announced the introduction of the Combo dual therapy stent during a breakfast symposium chaired by Martin B. Leon, M.D., professor of medicine and director of the...
November 14, 2011 – The TWENTE clinical trial, which compared Resolute versus Xience V drug-eluting stents in a real-world population established non-inferiority between the two stents as measured...
November 11, 2011 – Boston Scientific reported results from the EVOLVE first human use trial demonstrating the non-inferiority of the Synergy everolimus-eluting stent system compared to the Promus...
November 11, 2011 – Biosensors International Group announced two-year results from the BioFreedom first-in-human trial, which showed similar clinical outcomes between BioFreedom, a polymer-free,...
November 11, 2011 — The 30-day results from the 8,500+ patient ADAPT-DES registry were presented at the 2011 TCT conference in San Francisco. Patients with high platelet reactivity, as measured by...
November 9, 2011 — Currently under review by the U.S. Food and Drug Administration (FDA), the Resolute drug-eluting stent (DES) from Medtronic Inc. continues to demonstrate consistently positive...
November 8, 2011 — Biosensors International Group Ltd. announced final results of the AXXESS PLUS trial, which demonstrated the long-term efficacy and safety of the Axxess stent for patients with...
November 8, 2011 – Boston Scientific reports clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating excellent outcomes for the Promus Element everolimus-eluting platinum...
November 7, 2011 – Abbott announced the company's schedule of key data presentations at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, to be held Nov. 7 – 11...
November 7, 2011 – Arterial Remodeling Technologies (ART) reported that in vivo data strongly suggest that its second-generation bioresorbable stent promotes...
November 4, 2011 — Medtronic Inc. announced approval by the U.S. Food and Drug Administration (FDA) of the Assurant Cobalt Iliac Balloon-Expandable Stent System.
The U.S. Food and Drug Administration (FDA) granted market clearance for the Xience Prime everolimus-eluting coronary stent system for the treatment of coronary artery disease. The stent uses the...
November 1, 2011 – Boston Scientific released the schedule of its major events and product-related clinical research for the Cardiovascular Research Foundation's (CRF) 23rd annual Transcatheter...
October 25, 2011 — Stentys S.A. announced the publication of the results of the APPOSITION I clinical study in the September issue of the medical journal EuroIntervention.
October 24, 2011 — BioCrossroads’ Indiana Seed Fund has announced its twelfth investment, committing $300,000 to medical device start-up Zorion Medical. Zorion is developing a...
October 18, 2011 — Abbott announced the investigational Absorb bioresorbable vascular scaffold (BVS) has been recognized as the winner of the Medical Devices category in the 2011 Wall Street...
October 18, 2011 — Boston Scientific Corp. has begun a phased launch of its Promus Element everolimus-eluting platinum chromium coronary stent system in China. The launch campaign will be expanded...
A U.S. Food and Drug Administration (FDA) review panel has given its unanimous recommendation for the market approval of the Zilver PTX stent. It is the first device of its kind on several fronts...
October 5, 2009 – In a breakthrough development that could dramatically reduce the number of leg amputations and painful bypass graft surgeries performed annually on European patients, a first-of-...
January 20, 2011 – Drug-coated stents hold promise as a safe and lasting solution for the treatment of clogged leg arteries, suggest two-year results of the Zilver PTX Trial being presented at the...
October 7, 2011 — Boston Scientific Corp. has started patient enrollment in the Omega clinical trial, designed to evaluate the company's Omega platinum chromium bare-metal coronary stent system....
October 7, 2011 — Biosensors has announced completion of its acquisition of JW Medical Systems Ltd. (JWMS), one of the top three suppliers of drug-eluting stents (DES) in China.
Abbott began enrolling U.S. patients in the EXCEL trial, which will compare the use of the Xience Prime or Xience V drug-eluting strents to coronary artery bypass graft (CABG) surgery for...
October 3, 2011 – Maquet Cardiovascular has signed a definitive agreement to acquire Atrium Medical Corp. for $680 million. Atrium is a medical device technologies developer for...
September 30, 2011 — Boston Scientific Corp. said the U.S. Court of Appeals for the Federal Circuit found in favor of the company in a 1998 stent patent infringement suit involving Johnson &...
September 22, 2011 — Stentys S.A., a medical technology company commercializing a self-apposing stent to treat acute myocardial infarction (AMI), announced it has enrolled the 500-patient target...
